<DOC>
	<DOC>NCT02192567</DOC>
	<brief_summary>This is an open-label, sequential dose escalation and expansion study to evaluate the safety, and pharmacokinetics of DS-5573a in Japanese patients with advanced solid malignant tumors.</brief_summary>
	<brief_title>Open Label Study of DS-5573a</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Advanced solid tumor that is refractory to standard treatment, or for which no standard treatment is available. Eastern Cooperative Oncology Group performance status(PS) of 0 or 1 Have any of the following concomitant disease or had the history of having following disease within 6 months before enrollment: Cardiac failure (NYHA â‰¥ ClassIII), myocardial infarction, cerebral infarction, unstable angina, arrhythmia requiring treatment, coronaryartery/peripheral artery bypass surgery, cerebrovascular disease, pulmonary thromboembolism, uncontrolled deepvein thrombosis or clinically severe thromboembolic event, or autoimmune disorders requiring treatment. Severe or uncontrolled concomitant disease. Clinically active brain metastases defined as symptomatic or requiring treatment.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced solid malignant tumor</keyword>
	<keyword>phase 1</keyword>
	<keyword>oncology</keyword>
</DOC>